Soleno Therapeutics(SLNO) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total net revenue for Q4 2025 was $91.7 million, representing a sequential growth of nearly 40% from $66 million in Q3 2025. Full year revenue was $190.4 million, achieved in less than nine months of sales [4][19] - The company achieved profitability with a net income of $20.9 million for the full year 2025, compared to a net loss of $175.9 million for 2024 [24][19] - Cash flow from operating activities in Q4 was $48.7 million, and the company ended the year with over $506 million in cash equivalents and marketable securities [4][19] Business Line Data and Key Metrics Changes - VYKAT XR received 1,250 patient start forms since its launch, capturing approximately 12.5% of the U.S. addressable market for Prader-Willi syndrome (PWS) [5][11] - Active treatment increased to 859 individuals by the end of Q4, up from 764 at the end of Q3, indicating successful adoption into clinical practice [11][5] - The cumulative launch-to-date discontinuation rate for VYKAT XR related to adverse events was approximately 12% as of the end of Q4, with an expected long-term discontinuation rate of 15%-20% [6][5] Market Data and Key Metrics Changes - The company identified approximately 9,500 individuals living with PWS in the UK and EU4, with a concentrated market driven by centers of excellence [9] - The company secured broad coverage for VYKAT XR across all channels, covering over 180 million lives by the end of Q4 [15] Company Strategy and Development Direction - The company plans to expand beyond PWS, targeting additional metabolic rare disease indications, starting with Glycogen Storage Disease Type I (GSD I) [27] - The strategy includes leveraging the existing knowledge and skills from the VYKAT XR launch to address new indications with high unmet needs [29][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining momentum and capturing additional patient start forms over the next 9-12 months, indicating strong leading indicators [5][3] - The management acknowledged the complexity of PWS and the serious comorbidities of the patient population, emphasizing the importance of the real-world safety profile of VYKAT XR [6][5] Other Important Information - The company is preparing for potential approval of DCCR in the EU, with expectations for a decision in mid-2026 [8][7] - The CFO announced retirement at the end of March, with plans for a smooth transition to the new CFO [25][26] Q&A Session Summary Question: What is the expected cadence for the 1,000 patient start forms over the next 9-12 months? - Management indicated that the start forms will come in over the year rather than on a quarter-to-quarter basis [33][34] Question: What percentage of the market could be accessible in the U.S. for PWS? - Management suggested that a higher penetration than 40%-50% is possible given the lack of other treatments [39] Question: How are refill rates and average weight of new patients expected to change? - Management noted high adherence rates and expected that the average weight of new patients would likely increase over time due to more older patients being treated [42][44] Question: What is the company's strategy for exclusivity and patent prosecution for VYKAT XR? - Management confirmed ongoing efforts to extend exclusivity through additional IP filings and highlighted the potential for extending patents into the late 2030s [76] Question: What are the expectations for the EU approval process? - Management expressed cautious optimism, noting that they expect to receive Day 180 questions imminently and are prepared to address efficacy concerns raised by the EMA [82][81]